Autres langues Regeneron Pharmaceuticals, Inc.

Actions

REGN

US75886F1075

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 29/09/2026			Varia. 5j.	Varia. 1 janv.
750,51 ^USD	-0,23%		-6,64%	-2,77%

29/09	Regeneron a besoin de conditions « meilleures » dans la renégociation avec Sanofi, selon RBC	MT
28/09	Le programme de phase 3 de Pfizer sur le tilrekimig pourrait soutenir le titre, selon UBS	MT

Autres langues

29/09	Regeneron Needs 'Better' Terms in Sanofi Renegotiation, RBC Says
29/09	Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
28/09	Pfizer's Tilrekimig Phase 3 Program Seen as Potential Upside Driver, UBS Says
28/09	Biohaven Ltd. And Regeneron Pharmaceuticals, Inc. Enter Into Clinical Supply Agreement For BHV-1530 And Cemiplimab
28/09	US drugmakers turn to China for licensing deals
28/09	US drugmakers turn to China for licensing deals
25/09	US FDA approves Mirum's drug for rare bone disorder
24/09	Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
24/09	Regeneron Approaching Incremental Catalysts Like Upcoming Olatorepatide Data Readout, RBC Says
21/09	Telix to Buy Germany's ITM Isotope in Deal Worth Up to $2.35 Billion
10/09	MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
10/09	Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says
08/09	MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - RGRD Law
04/09	SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
02/09	Compañías que se deben tener muy en cuenta por técnico este miércoles en Wall Street
02/09	Valores destacados al cierre del mercado norteamericano
01/09	Regeneron Seen Weighing Expanded Sanofi Deal, RBC Says
29/08	Regeneron Pharmaceuticals Inc Initiates Recall of Libtayo (Cemiplimab-Rwlc) Injection, 350 Mg/7 Ml (50 Mg/Ml) For Intravenous Infusion After Dilution, Single-Dose Vial
27/08	AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial
25/08	Veeva Systems Secures Biogen, Regeneron Pharmaceuticals as New Vault CRM Clients
20/08	Pasatru (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial
19/08	Regeneron Announces Investor Conference Presentations
19/08	Regeneron Pharmaceuticals Wins US FDA Approval For Pasatru In Ultra-Rare Musculoskeletal Condition
19/08	US FDA approves Regeneron's rare bone disorder drug
19/08	Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)